PCSK9 and myocardial infarction: The second category of diseases includes the treatment of hypercholesterolemia to reduce the risk of myocardial infarction, via the disruption of proprotein convertase subtilisin/kexin type 9 (PCSK9) or other lipoprotein regulators in the liver (Cai et al., 2016[18]).